Alpha-1-Antitrypsin Deficiency

Alpha-1-antitrypsin deficiency (AATD) is one of the most common serious inherited disorders in adults of European descent, yet it remains dramatically underdiagnosed — most people wait five to seven years from first symptoms before receiving a correct diagnosis. The condition arises from mutations in a single gene that normally instructs the liver to produce a protective protein called alpha-1-antitrypsin (AAT). Without adequate circulating AAT, the lungs lose their defense against an enzyme that steadily erodes the air sacs, leading to emphysema in mid-life. At the same time, abnormally shaped AAT protein piles up inside liver cells, triggering a completely separate process that can lead to cirrhosis and liver cancer. Understanding AATD matters for anyone diagnosed with early-onset or unexplained lung disease, because specific therapies — including weekly intravenous infusions of replacement protein and, for advanced liver disease, organ transplantation — can substantially change the trajectory of the illness.

Table of Contents

  1. Overview and History
  2. Genetics and Molecular Biology
  3. Pathophysiology
  4. Pulmonary Manifestations
  5. Hepatic Manifestations
  6. Diagnosis
  7. Treatment
  8. Monitoring and Prognosis
  9. Key Research Papers
  10. References
  11. Connections

Overview and History

Alpha-1-antitrypsin deficiency was first described in 1963 by Swedish physicians Carl-Bertil Laurell and Sten Eriksson, who noticed the absence of a protein band on serum electrophoresis in five of 1,500 samples they were examining for unrelated purposes. Three of those five individuals had emphysema at an unusually young age — a striking observation that linked the missing protein to lung destruction. That foundational paper established the entire field of protease-antiprotease imbalance in lung disease.

AAT is a serine protease inhibitor (serpin) produced almost entirely by hepatocytes. Its primary function is to shield the delicate alveolar walls of the lung from neutrophil elastase — an enzyme that immune cells release during infection and inflammation to digest bacteria, but that will also digest lung tissue if left unchecked. In healthy people, circulating AAT forms a chemical firewall around the alveoli. In AATD, this firewall is either too thin or entirely absent.

AATD is classified as a rare disease but is common within that category. The most severe genotype, PiZZ, affects approximately 1 in 3,500 people of European ancestry — a prevalence similar to cystic fibrosis. Globally, an estimated 3.4 million people have severe AATD, though only a small fraction have been formally diagnosed. Awareness campaigns led by organizations such as the Alpha-1 Foundation have steadily improved detection rates since the 1990s.

Back to Table of Contents

Genetics and Molecular Biology

The gene responsible for AATD is SERPINA1, located on chromosome 14q32.13. It belongs to the serpin superfamily of protease inhibitors and encodes a 394-amino acid glycoprotein that circulates at concentrations of 100 to 200 mg/dL in healthy adults. Inheritance follows an autosomal codominant pattern, meaning both copies of the gene are expressed and both contribute to circulating AAT levels.

Alleles are named using the Pi (protease inhibitor) nomenclature. The normal allele is Pi*M, and individuals with two copies (PiMM) have fully normal AAT levels. The two most clinically important deficiency alleles are:

Common genotypes and their approximate AAT levels relative to normal:

Rare null alleles (Pi*Q0) produce no detectable AAT protein at all and cause severe lung disease without liver disease, since there is no misfolded protein to accumulate in the liver. More than 200 SERPINA1 variants have been catalogued, though Z and S account for the vast majority of clinically significant deficiency.

Back to Table of Contents

Pathophysiology

AATD causes disease through two mechanistically distinct pathways that operate largely independently of each other. This is a crucial concept: a patient can have severe lung disease with mild liver involvement, severe liver disease with mild lung disease, or both together. The two processes do not amplify each other.

Lung Disease: Loss-of-Function

AAT's primary role in the lung is to inhibit neutrophil elastase (NE) — a powerful serine protease stored in azurophil granules of neutrophils. During inflammation, neutrophils flood into the lung and release NE to destroy pathogens. In healthy lungs, AAT rapidly binds and neutralizes NE before it can damage surrounding tissue, forming a 1:1 inhibitory complex that is then cleared. When AAT levels fall below a critical threshold (approximately 57 mg/dL, the so-called "protective threshold"), NE activity goes unchecked. Over years, this enzymatic activity degrades elastin and collagen in alveolar walls, expanding and merging air sacs in a pattern called panacinar emphysema.

In contrast to smoking-related emphysema, which preferentially destroys the upper lobes through a centrilobular pattern, AATD emphysema starts in the lower lobes and is panacinar (the entire acinus is destroyed). This lower-lobe predominance on high-resolution CT is a diagnostic clue. Cigarette smoking dramatically accelerates the process by two mechanisms: it recruits vastly more neutrophils into the airways (amplifying NE burden) and it oxidizes the methionine residue at position 358 in AAT's reactive site loop, rendering even the limited circulating AAT functionally inactive. A smoking PiZZ patient can lose lung function three to four times faster than a non-smoking PiZZ patient.

Liver Disease: Gain-of-Toxic-Function

The Z-AAT protein's misfolding causes it to form ordered polymers that are retained inside hepatocyte endoplasmic reticulum. These polymers trigger a cascade of ER stress responses, impair autophagy (the cell's normal protein clearance pathway), and ultimately cause hepatocyte apoptosis and necrosis. Over decades, this ongoing hepatocyte loss — combined with cycles of repair and fibrosis — can progress to cirrhosis and hepatocellular carcinoma.

This gain-of-toxic-function mechanism explains a remarkable clinical observation: liver transplantation cures both the liver disease and the lung deficiency simultaneously. The transplanted liver carries the donor's functional SERPINA1 genotype, begins producing normal AAT, and eliminates the polymer-accumulating hepatocytes. Patients who receive a liver transplant for AATD-related cirrhosis convert from a PiZZ phenotype to the donor's phenotype (usually PiMM) and, if transplanted before severe lung disease develops, may never need augmentation therapy.

Back to Table of Contents

Pulmonary Manifestations

Lung disease is the most common reason patients with AATD come to medical attention. The typical presentation is progressive dyspnea on exertion starting in the 30s or 40s — often initially attributed to asthma, deconditioning, or smoking — in someone with a family history of early-onset lung disease or emphysema "despite never smoking much."

Emphysema is the hallmark manifestation. High-resolution CT (HRCT) of the chest shows panacinar destruction with lower-lobe predominance, often with bullae (large air-filled spaces) at the lung bases. Hyperinflation flattens the diaphragm. Spirometry reveals obstruction: a reduced FEV1/FVC ratio (below 0.70) with reduced FEV1 and an elevated residual volume and total lung capacity. Diffusing capacity (DLCO) falls as the alveolar surface area is lost.

In untreated PiZZ patients who smoke, FEV1 declines at approximately 80 to 150 mL per year — compared with 20 to 30 mL per year in normal aging and about 54 mL per year in non-smoking PiZZ patients. This dramatic acceleration means that a smoking PiZZ patient may reach severe COPD (FEV1 <30% predicted) by age 40 to 50.

Additional pulmonary features include:

The Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines recommend measuring serum AAT levels in all patients diagnosed with COPD, regardless of smoking history — a recommendation that remains underimplemented in clinical practice.

Back to Table of Contents

Hepatic Manifestations

Liver disease in AATD spans the entire lifespan and affects a spectrum of severity. Unlike the lung disease, liver disease in AATD is independent of environmental triggers such as smoking — it is driven solely by the accumulation of Z-AAT polymers inside hepatocytes.

In infants and children, AATD is one of the most common genetic causes of liver disease presenting in the newborn period. Approximately 10 to 20% of PiZZ infants develop neonatal cholestasis — prolonged jaundice and elevated direct bilirubin beyond two weeks of age. Most resolve spontaneously by six to twelve months, but roughly 10% progress to childhood cirrhosis. Interestingly, the other 80 to 90% of PiZZ infants have no clinically apparent liver disease in childhood, suggesting that modifier genes and environmental factors determine who develops liver injury.

In adults, PiZZ individuals face a cumulative risk of clinically significant liver disease of approximately 50% by age 50, rising further with age. The spectrum includes:

On liver biopsy, the pathognomonic finding is PAS-D-positive (periodic acid-Schiff diastase-resistant) globules in periportal hepatocytes — rounded pink inclusions that represent the accumulated Z-AAT polymers. This pattern is virtually diagnostic of AATD on liver biopsy and should prompt confirmatory genetic testing.

A rarer but important extra-hepatic manifestation is panniculitis — painful, recurring subcutaneous nodules, usually on the trunk and proximal extremities, that break down and discharge a clear oily liquid. This lobular panniculitis is caused by unchecked protease activity in subcutaneous fat and responds to augmentation therapy (replacing AAT systemically) and occasionally to dapsone.

Back to Table of Contents

Diagnosis

AATD is commonly delayed or missed because its symptoms — breathlessness, chronic cough, abnormal liver enzymes — are attributed to other causes. A structured approach combines blood tests, genetic analysis, and imaging.

Serum AAT Level

The first-line test is a serum AAT level by nephelometry or immunoturbidimetry. A level below 80 mg/dL is suspicious; below 57 mg/dL represents severe deficiency (the "protective threshold"). Because AAT is an acute-phase reactant, levels can rise temporarily during inflammation, infection, pregnancy, or oral contraceptive use — a normal level during an acute illness does not exclude AATD, and retesting when the patient is well may be warranted.

Pi Phenotyping and Genotyping

Isoelectric focusing (IEF) of serum proteins separates AAT variants by their charge characteristics and is considered the phenotyping gold standard — it can identify Pi*M, Pi*Z, Pi*S, and rarer variants simultaneously. Genotyping by PCR specifically detects the most common Z and S alleles and is used for family screening and confirmation; however, rare variants require IEF or full gene sequencing. The combination of a low serum level plus genotyping identifies the vast majority of clinically significant cases.

Pulmonary Evaluation

Hepatic Evaluation

Family Screening

Because AATD is inherited, all first-degree relatives (siblings and biological children) of a diagnosed PiZZ individual should be offered testing. Parents of a PiZZ child are each Pi*MZ carriers (or one parent is PiZZ). Counseling should cover the importance of lifelong smoking avoidance and the risk of passing the allele to children.

Back to Table of Contents

Treatment

Treatment targets both organ systems independently. No single drug addresses both the lung and liver disease simultaneously — except liver transplantation, which by replacing the SERPINA1 genotype reconstitutes AAT production and cures both.

Pulmonary Management

Standard COPD management forms the foundation:

Augmentation Therapy

Augmentation (replacement) therapy is unique to AATD and has no equivalent in other forms of COPD. It consists of weekly intravenous infusions of purified human AAT protein pooled from plasma donors, raising serum levels above the protective threshold of 57 mg/dL. Four preparations are licensed in the United States: Prolastin-C (Grifols), Aralast NP (Takeda), Zemaira (CSL Behring), and Glassia (Takeda).

The landmark RAPID trial (Chapman et al., Lancet 2015) demonstrated that augmentation therapy significantly slowed the decline in CT-measured lung density over two years compared with placebo — providing the first definitive evidence of efficacy from a randomized controlled trial. The effect size was modest but clinically meaningful, and longer follow-up in the RAPID-OLE (open-label extension) study confirmed durability. Current guidelines from the American Thoracic Society recommend augmentation for PiZZ or PiSZ patients with FEV1 between 20% and 65% predicted who are not current smokers. It does not reverse existing emphysema; it slows progression.

Augmentation therapy does not treat liver disease — the infused AAT is not taken up by hepatocytes, and the polymer accumulation in liver cells continues regardless of serum AAT levels.

Liver Management

No approved pharmacotherapy currently slows Z-AAT polymer accumulation in the liver. Management of complications follows standard hepatology practice: beta-blockers for portal hypertension, banding for varices, sodium restriction and diuretics for ascites, and monitoring for HCC. Liver transplantation is indicated for end-stage liver disease and has the unique advantage of curing both the liver disease and the AAT deficiency simultaneously.

Emerging Therapies

Fazirsiran (ARO-AAT), an RNA interference (RNAi) agent that silences hepatic SERPINA1 expression, reduces Z-AAT polymer formation in hepatocytes. A Phase 2 trial published in the New England Journal of Medicine in 2022 (Strnad et al.) demonstrated significant reductions in liver Z-AAT accumulation and improvements in liver histology. Phase 3 trials are ongoing. Other investigational approaches include small-molecule correctors (analogous to CFTR modulators in cystic fibrosis) that attempt to restore correct folding of the Z-AAT protein, and gene therapy approaches targeting stable SERPINA1 replacement in hepatocytes.

Back to Table of Contents

Monitoring and Prognosis

Long-term monitoring coordinates pulmonary and hepatic surveillance and includes family cascade screening.

Pulmonary Monitoring

Hepatic Monitoring

Prognosis

Prognosis varies enormously based on genotype, smoking history, and early detection. A non-smoking PiZZ individual diagnosed before significant lung damage can have a near-normal life expectancy, particularly if augmentation therapy is started early. Smoking PiZZ patients who are not diagnosed until moderate COPD (FEV1 40 to 60% predicted) face a substantially shortened lifespan. Data from Swedish registries show that median survival for PiZZ patients who never smoked is only modestly below that of the general population, while survival for PiZZ smokers is significantly reduced — emphasizing that this is largely a preventable disease once the diagnosis is made.

The greatest public health opportunity lies in earlier diagnosis: universal newborn screening programs (implemented in several European countries) identify AATD at birth, enabling family counseling and lifelong smoking prevention. In adults, routine testing of all COPD patients as recommended by GOLD guidelines would identify thousands of undiagnosed cases annually in the United States alone.

Back to Table of Contents

Key Research Papers

The following PubMed searches bring up current literature on each aspect of AATD:

Back to Table of Contents

References

  1. Laurell CB, Eriksson S. The electrophoretic alpha1-globulin pattern of serum in alpha1-antitrypsin deficiency. Scand J Clin Lab Invest. 1963;15:132-140. doi:10.3109/00365516309051324
  2. Stoller JK, Aboussouan LS. Alpha1-antitrypsin deficiency. Lancet. 2005;365(9478):2225-2236. PMID: 15978931. doi:10.1016/S0140-6736(05)66781-5
  3. Lomas DA, et al. The mechanism of Z alpha 1-antitrypsin accumulation in the liver. Nature. 1992;357(6379):605-607. PMID: 1608473. doi:10.1038/357605a0
  4. Chapman KR, et al. Intravenous augmentation treatment and lung density in severe alpha1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial. Lancet. 2015;386(9991):360-368. PMID: 26026936. doi:10.1016/S0140-6736(15)60167-X
  5. Strnad P, et al. Fazirsiran for Liver Disease Associated with Alpha-1 Antitrypsin Deficiency. N Engl J Med. 2022;387(6):514-524. PMID: 35944209. doi:10.1056/NEJMoa2205416
  6. Tanash HA, et al. Survival in individuals with severe alpha 1-antitrypsin deficiency (PiZZ) in comparison with a general population with known smoking habits. Eur Respir J. 2010;36(6):1295-1301. PMID: 20530036. doi:10.1183/09031936.00198309
  7. Teckman JH, et al. Liver disease in alpha-1 antitrypsin deficiency: the emerging role of ER stress. Hepatology. 2002;36(6):1477-1483. PMID: 12447877. doi:10.1053/jhep.2002.37387
  8. Sandhaus RA, et al. An Official American Thoracic Society Clinical Practice Guideline: Genetic Risk Factors for COPD. Am J Respir Crit Care Med. 2016;194(7):e23-e36. PMID: 27669587. doi:10.1164/rccm.201607-1384ST
  9. Janciauskiene SM, et al. The discovery of alpha1-antitrypsin and its role in health and disease. Respir Med. 2011;105(8):1129-1139. PMID: 21565479. doi:10.1016/j.rmed.2011.02.002
  10. Ferrarotti I, et al. Serum levels and genotype distribution of alpha1-antitrypsin in the general population. Thorax. 2012;67(8):669-674. PMID: 22436168. doi:10.1136/thoraxjnl-2011-201321
  11. Dawwas MF, et al. Survival after liver transplantation in the United Kingdom and Ireland: effect of programme size. Gut. 2007;56(11):1555-1562. PMID: 17369375. doi:10.1136/gut.2006.111146
  12. O'Brien ML, et al. Polymorphisms in the promoter region of the alpha1-antitrypsin gene and pulmonary emphysema. Am J Respir Crit Care Med. 1997;155(5):1571-1576. PMID: 9154862. doi:10.1164/ajrccm.155.5.9154862

Back to Table of Contents

Connections

Back to Table of Contents